{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:20:58Z","timestamp":1780514458280,"version":"3.54.1"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>This Viewpoint reports on the potential of benzoyl peroxide\u2013containing products to form benzene, a carcinogen, and the need to carefully monitor the use of benzoyl peroxide in skin care and other benzoyl peroxide\u2013containing products.<\/jats:p>","DOI":"10.1001\/jamadermatol.2025.1694","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T11:01:20Z","timestamp":1750244480000},"page":"791","source":"Crossref","is-referenced-by-count":3,"title":["Benzoyl Peroxide\u2013Containing Products and Benzene"],"prefix":"10.1001","volume":"161","author":[{"given":"John S.","family":"Barbieri","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Program in Translational Biomedicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"dvp250001r1","doi-asserted-by":"publisher","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris.","volume":"90","author":"Reynolds","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"dvp250001r2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jid.2024.09.009","article-title":"Evaluation of benzene presence and formation in benzoyl peroxide drug products.","volume":"145","author":"Kucera","year":"2025","journal-title":"J Invest Dermatol"},{"issue":"4","key":"dvp250001r3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jamadermatol.2024.6443","article-title":"The role of formulation in benzene formation in benzoyl peroxide products.","volume":"161","author":"Barbieri","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"4","key":"dvp250001r6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jaad.2024.06.050","article-title":"No evidence for an association between benzoyl peroxide use and increased blood benzene levels in the National Health and Nutrition Examination Survey.","volume":"91","author":"Sadr","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"dvp250001r7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.jaad.2024.07.011","article-title":"Benzoyl peroxide for acne treatment is not associated with an increased risk of malignancy: a retrospective cohort study.","volume":"91","author":"Garate","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"dvp250001r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.02.139","article-title":"A disproportionality analysis on benzoyl peroxide and its risk of malignancy using the FDA Adverse Event Reporting System.","author":"Yang","journal-title":"J Invest Dermatol"},{"key":"dvp250001r9","doi-asserted-by":"publisher","author":"Barbieri","journal-title":"J Invest Dermatol","DOI":"10.1016\/j.jid.2025.04.011"},{"key":"dvp250001r10","doi-asserted-by":"publisher","journal-title":"J Am Acad Dermatol","DOI":"10.1016\/j.jaad.2024.05.093"},{"key":"dvp250001r4","unstructured":"Reformulating drug products that contain carbomers manufactured with benzene. US Food and Drug Administration. December 2023. Accessed May 7, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/reformulating-drug-products-contain-carbomers-manufactured-benzene"},{"key":"dvp250001r5","unstructured":"Limited number of voluntary recalls initiated after FDA testing of acne products for benzene; findings show a small number of products with elevated levels of benzene contamination. US Food and Drug Administration (FDA). Published online March 11, 2025. Accessed March 15, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/limited-number-voluntary-recalls-initiated-after-fda-testing-acne-products-benzene-findings-show"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2835235\/jamadermatology_barbieri_2025_vp_250001_1755630703.81357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T15:00:33Z","timestamp":1755702033000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2835235"}},"subtitle":["Where Are We Now After Recalls, and How Should We Move Forward?"],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.1694","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}